We have demonstrated quality improvement in MS analysis of FFPE samples, which enabled the identification of differential proteomic profiles between IDH wild-type and IDH mutant gliomas, as well as among multiple areas of LGGs and GBMs, reflecting different molecular pathways [106,107]. The gene discussed is IDH2; the disease is central nervous system cancer.